NCT06828731

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Sodium-glucose Transporter 2 Inhibitor Use in Pre-diabetes: Initial Evaluation in Veterans

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Charles George VA Medical Center · Federal
• Sex: All
• Age: 35 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular events and kidney complications, both common and costly complications of diabetes. This is a 12-week, open-label pilot feasibility study assessing the use of empagliflozin in prediabetes.

Conditions

• Prediabetes

Interventions

Type	Name	Description
DRUG	Empagliflozin 10mg daily	This intervention will assess recruitment and retention (feasibility trial).
OTHER	Lifestyle education	This intervention is considered standard care for prediabetes.

Timeline

• Start date: 2024-12-06
• Primary completion: 2025-09-05
• Completion: 2025-09-05
• First posted: 2025-02-14
• Last updated: 2025-11-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study